July 24, 2023
BURLINGTON, Ontario – July 24, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $1,469,445 in a first tranche of its previously announced private placement financing (the “Financing”) for up to $5,000,000 of...
July 7, 2023
July 7, 2023 – Burlington, ON: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to share an update on its current progress in various segments of its business. The Annual General and Special Meeting of the shareholders of Rapid Dose Therapeutics...
June 29, 2023
Burlington, Ontario – June 28, 2023– Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), today reported its financial results for the year ended February 28, 2023. The Company is pleased to be able to report on its results for the fiscal year 2023...
June 5, 2023
BURLINGTON, Ontario – June 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete a private placement financing (the “Financing”) for up to $3,000,000 of gross proceeds, consisting of up to 3,000,000 units (the “Units”)...
May 18, 2023
BURLINGTON, Ontario – May 17, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that it has changed its auditor from MNP LLP (“Former Auditor”) to SRCO Professional Corporation, Chartered Professional Accountants (“Successor Auditor”). At the request of the Company, the...
May 10, 2023
BURLINGTON, Ontario – May 10, 2023- Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: ·...
May 4, 2023
BURLINGTON, Ontario – May 4, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that further to its press release dated May 2, 2023, trading in the Company’s common shares has resumed on the Canadian Securities Exchange. About...
May 2, 2023
BURLINGTON, Ontario – May 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that on May 1, 2023, staff of the Ontario Securities Commission (the “OSC”) granted a full revocation of the failure-to-file cease trade order (“FFCTO”)...
April 14, 2023
BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that further to the review by the Ontario Securities Commission (“OSC”) of the Company’s continuous disclosure record, and a subsequent request from staff of the OSC in...
April 14, 2023
BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors. Jason Lewis has resigned as a director of the...